18th CANADIAN MELANOMA CONFERENCE 2024: Bristol Myers Squibb Lunch Symposium: LAG 3 – Unveiling the 3rd Checkpoint Pathway – Dr. Hussein Tawbi

18th CANADIAN MELANOMA CONFERENCE 2024: Bristol Myers Squibb Lunch Symposium: LAG 3 – Unveiling the 3rd Checkpoint Pathway – Dr. Hussein Tawbi

Canadian Melanoma Conference 2024
Icon Objectives

Learning Objectives

  1. Describe key clinical trial data from 2023 in the management of melanoma and understand the impact on Canadian practices.
  2. Understand the latest strategies in melanoma as they pertain to medical oncology, pathology, radiation, and surgery.
  3. Implement approaches that maximize patient standard of care in melanoma
Icon Chair Speaker

Co-Chairs

Dr. Vanessa Bernstein
Dr. Teresa Petrella

Icon Chair Speaker

Speakers

Dr. Hussein Tawbi

This program has been made possible through unrestricted support from Bristol Myers Squibb

Tagged